Progress in the use of gene transfer methods to treat genetic blood diseases

Human Gene Therapy

Volumn 11, Issue 15, 2000, Pages 2059-2066

  Williams, D A ^a   Smith, F O ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD DISEASE; CLINICAL PROTOCOL; GENE TARGETING; GENE TRANSFER; HUMAN; MEDICAL RESEARCH; REVIEW;

ADENOVIRIDAE; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOLOGIC DISEASES; HUMANS; SAFETY; SEVERE COMBINED IMMUNODEFICIENCY; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; UNIDENTIFIED RETROVIRUS;

EID: 0034633741     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303400750001372     Document Type: Review

References (76)

1. Efficienct retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
2. In vivo selection of retrovirally transduced hematopoietic stem cells
3. Gene therapy. The best of times, the worst of times
4. Centrifugal enhancement of retroviral mediated gene transfer
5. The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF
6. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture
7. - SCID: Initial trial results after 4 years
8. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients
9. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
10. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells
11. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice
12. Vesicular stomatifis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells
13. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
14. Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers
15. Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells
16. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
17. Introduction of a selectable gene in primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice
18. Gene transfer into normal human hematopoietic cells using in vitro and in vivo assays
19. Helper virus induced T cell lymphoma in non-human primates after retroviral mediated gene transfer
20. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation
21. Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with gaucher disease. A phase I study
22. Improved retroviral gene transfer into murine and rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor
23. + cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo
24. Spumaviruses: A group of complex retroviruses
25. Direct evidence for multiple self-renewal divisions of human in vivo repopulating hematopoietic cells in short-term culture
26. Results of mdr-1 vector modification trial indicate that granulocyte/macrophage colongy-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy
27. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells
28. Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells
29. Versatile retroviral vectors for potential use in gene therapy
30. Virus receptors: Binding, adhesion strengthening, and changes in viral structure
31. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
32. High-efficiency gene transfer to human hematopoietic cells maintained in long-term marrow culture
33. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
34. Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor Cells
35. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
36. Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors
37. Highly efficient gene transfer into cord blood NOD/SCID repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein
38. Gene transfer into marrow repopulating cells: Comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons
39. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with IL-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor
40. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency
41. Improved methods of retroviral vector transduction and production for gene therapy
42. Site specific integration by adeno-associated virus
43. Efficient transduction by an amphotropic retrovirus vector is dependent on high-level expression of the cell surface virus receptor
44. High-efficiency gene transfer and expression in normal human hematopoietic cells with retrovirus vectors
45. Identification of primitive human hematopoietic cells capable of re-populating NOD/SCID mouse bone marrow: Implications for gene therapy
46. Developmental potential and dynamic behavior of hematopoietic stem cells
47. Gene therapy and the germline
48. Simultaneous infection with retroviruses pseudotyped with different envelope proteins bypasses viral receptor interference associated with colocalizatlon of gp70 and target cells on fibronectin CH-296
49. Prolonged detection of oxidase-positive neutrophils in the peripheral blood of five patients following a single cycle of gene therapy for chronic granulomatous disease
50. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease
51. Cell surface receptors for retroviruses and implications for gene transfer
52. Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry
53. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus
54. Stromal support allows efficient transduction of human bone marrow long term culture initiating cells by cell-free retroviral vector
55. Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors
56. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: Evidence of direct viral binding to chymotryptic carboxy-terminal fragments
57. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver
58. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
59. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice
60. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction
61. Identification of human and mouse hematopoietic stem cell populations expressing high levels of mRNA encoding retrovirus receptors
62. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells
63. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors
64. The RD114/simian type D retrovirus receptor is a neutral amino acid transporter
65. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells
66. Foamy virus vectors
67. Amphotropic or gibbon ape leukemia virus retrovirus binding and transduction correlates with the level of receptor mRNA in human hematopoietic cell lines
68. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1
69. A sodium-dependent neutral-amino-acid transporter mediates infections of feline and baboon endogenous retroviruses and simian type D retroviruses
70. A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family
71. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
72. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse
73. Prospects for fetal gene therapy